1	Cellular and Transcriptional Signature of the Nasal Mucosa is Associated with Susceptibility to
2	Pneumococcal Carriage in Older Adults
3	
4	Britta C. Urban <sup>1,2,3*</sup> , André N. A. Gonçalves <sup>1,2,3*</sup> , Dessi Loukov <sup>2</sup> , Fernando M. Passos <sup>2</sup> , Jesús Reiné <sup>1,2,3</sup> ,
5	Patrícia Gonzalez-Dias <sup>1,2,3</sup> , Carla Solórzano-Gonzalez <sup>1,2,3</sup> , Elena Mitsi <sup>1,2,3</sup> , Elissavet Nikolaou <sup>2,4,5</sup> , Daniel
6	O'Connor <sup>1,3</sup> , Andrea M. Collins <sup>2</sup> , Hugh Adler <sup>2</sup> , Jamie Rylance <sup>2</sup> , Stephen B. Gordon <sup>2,6</sup> , Simon P. Jochems <sup>7</sup> ,
7	Helder I. Nakaya <sup>8,9</sup> , Daniela M. Ferreira <sup>1,2,3</sup>
8	
9	Affiliations:
10	<sup>1</sup> Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
11	<sup>2</sup> Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
12	<sup>3</sup> NIHR Oxford Biomedical Research Centre, Oxford, UK
13	<sup>4</sup> Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria,
14	Australia
15	<sup>5</sup> Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and
16	Immunity, The University of Melbourne, Parkville, Victoria, Australia
17	<sup>6</sup> Malawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi
18	<sup>7</sup> Department of Parasitology, Leiden University Centre for Infectious Diseases, Leiden University
19	Medical Centre, Leiden, the Netherlands.
20	<sup>8</sup> Hospital Israelita Albert Einstein, São Paulo, Brazil.
21	<sup>9</sup> Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of
22	São Paulo, São Paulo, Brazil
23	
24	* These authors contributed equally
25	
26	Corresponding authors:
27	Britta Urban, Britta.urban@paediatrics.ox.ac.uk
28	Daniela Ferreira, <u>Daniela.ferreira@paediatrics.ox.ac.uk</u>
29	
30	Word Count: 4172
31	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 32 Contributions:
- 33 Obtained funding: SBG, DMF
- 34 Study design: HA, DMF, JRy
- 35 **Obtained ethical approval:** HA, JRy
- 36 Data collection: HA, AC, JR, SJ, CS, EM, EN
- 37 Data analyses: DL, FMP, BU, ANAG, PGD
- 38 Manuscript preparation: BU, ANAG, DO, DMF, HN, SJ
- 39
- 40 All authors contributed to the manuscript and approved the final version submitted for publication.
- 41
- 42

#### All rights reserved. No reuse allowed without permission.

#### 43 Abstract

44 Streptococcus pneumoniae colonization in the upper respiratory tract is linked to pneumococcal disease development, predominantly affecting the very young and older adults. As the global 45 population ages and comorbidities increase, there is a heightened concern about this infection. We 46 investigated the immunological responses of older adults to pneumococcal controlled human 47 infection by analysing the cellular composition and gene expression in the nasal mucosa. Our 48 49 comparative analysis with younger adults revealed distinct gene expression patterns in older 50 individuals susceptible to colonization, highlighted by neutrophil activation and elevated levels of 51 CXCL9 and CXCL10. Unlike younger adults challenged with pneumococcus, older adults did not show recruitment of monocytes into the nasal mucosa following nasal colonization. These findings suggest 52 53 age-associated cellular changes, in particular enhanced mucosal inflammation, that may predispose older adults to pneumococcal colonization. If similar changes are observed in the lung of susceptible 54 55 older adults, these may explain the increased risk of pneumococcal disease in vulnerable populations.

56

#### 57 Introduction

Streptococcus pneumoniae is the primary cause of bacterial pneumonia and can reside in the upper 58 59 respiratory tract without causing symptoms. Colonization with pneumococcus is a prerequisite of pneumococcal disease, with higher colonization levels increasing the risk of bacteria entering the 60 61 lung<sup>1</sup>. Invasive pneumococcal disease and community-acquired pneumonia are a leading cause of death worldwide. Community-acquired pneumonia affects young children (below five years) and older 62 adults disproportionally<sup>2-6</sup>. With an aging population and rising prevalence of comorbidities such as 63 64 COPD, obesity, diabetes, and asthma, the incidence of pneumonia is predicted to grow.

Our pneumococcal controlled human infection model is an ideal model to investigate molecular and 65 66 cellular mechanisms that contribute to protection or susceptibility to colonization by pneumococci<sup>7</sup>. Using this model in young adults, we have shown that both innate and adaptive immune responses at 67 68 the mucosa were associated with protection from colonization. We have also shown that colonization 69 is typically established within a day after nasal exposure, ultimately prompting a local immune 70 response that clears the pneumococci<sup>8</sup>. This response included the activation of neutrophils and a likely CCL2-mediated influx of monocytes, resulting in bacterial clearance through processes like 71 72 phagocytosis and the release of reactive oxygen species<sup>9</sup>. Younger individuals resistant to colonization have more mucosal-associated invariant T cells (MAIT) in their nasal mucosa and in the peripheral 73 circulation exhibit elevated TNF $\alpha$  and IFNy levels when exposed to Spn6B<sup>10</sup>. In addition, young study 74 75 participants protected from colonization showed a higher frequency of pre-existent peripheral blood memory B cells specific to the polysaccharide of the inoculated strain<sup>11</sup>. Moreover, colonization itself 76

77 is an immunising event that results in increased antigen-specific B cells in circulation and higher levels of serum antibodies<sup>10,11</sup>. Although the impact of the SARS-CoV-2 pandemic increased the number of 78 79 studies investigating mucosal immune, they remain rare in older adults. As a consequence, whether 80 similar mechanisms are involved in protection and susceptibility of older adults from pneumococcus 81 infection is not known.

82 Older adults face a higher risk of severe pneumococcal disease than younger adults. While other factors such as co-morbidities, increased lung microaspiration and viral co-infections may contribute 83 to this increased risk<sup>12</sup>, altered immune responses due to aging also play an important role<sup>13–15</sup>. In our 84 85 study, when we exposed healthy older adults (over 50 years) to pneumococcus, their colonization rates and densities mirrored that of younger adults<sup>16</sup>. However, their immune response differed – 86 87 those who became colonized did not exhibit the expected boost in specific IgG against the inoculated 88 strain capsular polysaccharide (CPS), as seen in younger adults<sup>16</sup>. In addition, in those participants who were challenged and did not become colonized, IgG levels to the CPS decreased a month after 89 90 challenge. Re-challenging them with homologous pneumococcus 6B up to a year later did not protect 91 older adults from colonization, unlike in younger adults where re-challenge conferred protection<sup>7,16</sup>. 92 Together, these findings suggest a diminished immunizing effect of colonization in older adults, 93 potentially increasing their vulnerability to severe pneumococcal disease even with lower colonization 94 rates<sup>17</sup>.

95 To gain a better understanding of mechanisms underlying the lack of protection, we investigated here 96 the changes in cellular composition, inflammatory status and gene expression patterns of nasal cells 97 from older adults before and during experimental human pneumococcal colonization. We then compared these changes with those from younger adults<sup>9,18</sup>. Older but not younger adults susceptible 98 99 to colonization displayed a distinct pattern of activated gene pathways associated with neutrophil 100 degranulation and increased concentrations of CXCL9 and CXCL10 in the nasal mucosa at baseline. Our 101 results open the possibility of predicting susceptibility to pneumococcal colonization and greater risk of pneumococcal disease in older adults which would facilitate better prevention and treatment. 102

103

#### 104 Results

#### 105 Distinct gene expression patterns in the nasal mucosa of older adults linked to carriage susceptibility

We previously conducted an experimental human pneumococcal challenge trial in healthy, older 106 107 adults<sup>16</sup> during which we collected nasal lining fluid and nasal microbiopsies to determine soluble 108 immune mediators, nasal cell phenotype and transcriptome from a subset of study participants. An 109 overview of the sample schedule relative to inoculation with serotype 6B (Spn6B) for older adults is

All rights reserved. No reuse allowed without permission.

provided in Supplementary Fig. 1. No demographic differences were seen between study participants
 susceptible (n=17) or protected (n=24) from colonization (Supplementary Table 1).

We first investigated which immune response pathways were enriched in protected and susceptible 112 113 older adults before (day -5) and after (day 2 and day 9) pneumococcal challenge using gene set variation analysis (GSVA) (Fig. 1a, Supplementary Table 2). Based on Euclidean distance clustering, 114 115 gene sets fell into three groups with different enrichment patterns over time and carriage status. 116 Group I gene sets were associated with innate immune responses and cytokine signalling including 117 pathways associated with "Antimicrobial peptides", "Neutrophil degranulation", "DAP12 interactions" 118 and "Toll-like receptor cascades". They remained higher across all time points in susceptible older adults but were not induced in protected older adults. By contrast, group II gene sets were largely 119 associated with antibody-mediated processes such as "Complement Cascade" and "Fc gamma 120 121 receptor dependent phagocytosis". These pathways were predominantly enriched at baseline (day -5) in protected older adults and induced in susceptible older adults by day 9. Group III gene sets 122 123 associated with antigen presentation and T cell activation and were induced in susceptible study 124 participants on day 9.

125 We then asked whether similar gene pathway patterns were evident in younger adults before 126 pneumococcal challenge using a control group from our previously published studies (protected n=6, susceptible n=8, age < 50 years)<sup>9,18</sup>. In younger adults, GSVA of the nasal cell transcriptome showed 127 no difference in the regulation of group I gene or group II gene sets at baseline, between protected 128 129 and susceptible study participants. However, gene pathways in both groups were rapidly induced after 130 pneumococcal challenge in susceptible younger adults indicating activation of innate and antibody-131 mediated immune responses (Fig 1b, Supplementary Table 3). By contrast, activation of gene sets in 132 group III associated with "TCR signalling", "Costimulation by the CD28 family" and MHC class I and class II antigen processing were enriched in susceptible younger adults at baseline. In summary, gene 133 134 expression patterns in the nasal mucosa were fundamentally different between susceptible younger 135 and older adults, with susceptible older adults exhibiting a unique gene set signature associated with 136 an activated innate immune response profile before pneumococcal challenge.

137

# Co-expression analysis of genes reveals upregulation of neutrophil degranulation pathways in the nasal mucosa of susceptible older adults

140 Co-expression analysis allows identification of genes which are co-regulated during cellular processes 141 or different functional states and which are shared within a sample group. We therefore investigated 142 which genes were co-expressed in susceptible and protected older adults using CEMiTool<sup>19</sup> across all 143 three timepoints. Co-expression analysis identified three modules (M1-M3, Fig. 2a) with module M1

All rights reserved. No reuse allowed without permission.

genes co-expressed in protected and M2 genes co-expressed in susceptible older adults at baseline.
Notably, genes within the M2 module were enriched for the Reactome pathways "Neutrophil
Degranulation", "Immunoregulatory interactions between a Lymphoid and a Non-lymphoid Cell" and
"Signalling by Interleukins" (Supplementary Fig. 2) which were also among upregulated gene sets in
susceptible older adults identified by GSVA.
We then identified genes in the M2 module linked to carriage susceptibility by examining which ones

- 150 were differentially expressed between susceptible and protected older adults. Module M2 identified 151 270 co-expressed genes (Supplementary Fig. 2) of which 216 were differentially expressed at at least 152 one timepoint (Supplementary Table 4). Network analysis of genes overexpressed in susceptible study 153 participants before challenge (Fig. 2b) revealed a more granular picture of interlinked immune 154 response pathways. Genes overexpressed within the neutrophil degranulation pathway at baseline in 155 susceptible study participants included SIGLEC14 (2.42-fold, p=0.037), encoding a sialic acid binding protein and PLAUR (2.13-fold, p=0.012), encoding the Plasminogen Activator Urokinase receptor. 156 157 Notably, the expression of PLAUR is upregulated by immune activation and the soluble form has been proposed as a marker for chronic inflammation<sup>20</sup>. Both, *SIGLEC14* and *TREM1* (4-fold, p=0.0028) which 158 is induced two days after challenge signal through the DAP12 (TYROBP, 2.3-fold, p=0.027)) complex 159 160 resulting in enhanced survival of immune cells and increased production of pro-inflammatory 161 cytokines<sup>21,22</sup>. In a mouse model of pneumococcal pneumonia, TREM1 is critical for migration of neutrophils to the lung and enhanced early response of alveolar macrophages<sup>23</sup>. Of the Fc receptors, 162 FCAR encoding the Fc $\alpha$ R was 3.13-fold overexpressed at baseline (p=0.0078) whereas genes encoding 163 Fcy receptors were induced on days 2 and 9 after pneumococcal challenge (Fig. 2c). Of the M2 cytokine 164 and chemokine genes, IL1B (2.6-fold, p=0.016) and CXCL8 (3.4-fold, p=0.0031) showed higher 165 166 expression in nasal cells of susceptible compared with protected older adults at baseline.
- 167

Increased baseline expression of CXCL9 and CXCL10 in the nasal mucosa of susceptible older adults 168 169 Given the increased expression of genes associated with innate immune and cytokine responses in 170 susceptible older adults, we asked whether transcriptional changes are at least in part reflected at the 171 protein level in the nasal mucosa (Fig. 3 and Supplementary Fig. 3). The median concentration of the 172 chemokine CXCL10 (IP10) was 2.27-fold higher before (day -5) and 3.4-fold higher on day 2 in nasal 173 lining fluid after challenge in susceptible compared with protected study participants. Likewise, the 174 concentration of the related chemokine CXCL9 was 1.16-fold increased at baseline (day -5) in 175 susceptible older adults (Fig. 3a). Expression of the genes encoding these two chemokines were also 176 increased in susceptible compared with protected older adults at baseline only (Fig. 3b, CXCL9 2.1-177 fold, p=0.021); CXCL10 2.6-fold, p=0.003). These data are reminiscent of younger adults with an

All rights reserved. No reuse allowed without permission.

178 asymptomatic viral infection or receiving Live Attenuated Influenza Vaccine (LAIV), who showed high baseline levels of CXCL10 and increased susceptibility to pneumococcal colonization upon challenge<sup>9</sup>. 179 180 As with younger adults, there were no differences between CCL2 concentrations between susceptible 181 and protected older adults. Unlike in younger adults, we did not observe an association between CCL2 concentration and the frequency of monocytes in the nasal mucosa (Supplementary Fig. 4). However, 182 183 CCL2 gene expression was 4 times higher in susceptible compared to protected older adults at day 9 184 after challenge suggesting that monocyte recruitment might be delayed. In addition, the 185 concentration of IL-15, a cytokine which regulates T cell proliferation and activation, gradually 186 increased in protected study participants after challenge and was 1.3-fold higher at day 9 compared 187 to susceptible study participants. There were no statistically significant differences between protected 188 and susceptible study participants before and after pneumococcal challenge for all other cytokines 189 analysed (Supplementary Fig. 3a).

190 When considering induction of cytokines within each group of susceptible or protected study 191 participants (log<sub>2</sub> fold change for day 2, 7 and 9 against baseline), we observed responses to 192 pneumococcal challenge in the nasal mucosa of protected but not susceptible study participants (Fig. 193 3c and Supplementary Table S5). EGF significantly increased from baseline in protected study 194 participants on days 2 and 9 and VEGF and G-CSF increased on day 2. In protected study participants, 195 the concentration of the monocyte chemoattractant MIP1 $\alpha$  and MIP1 $\beta$ , as well as CXCL9 and IL12 196 increased from baseline to day 2. The pro-inflammatory cytokines IL1 $\beta$  and IL6 were also induced. This is in contrast to observations in protected younger adults<sup>8,9</sup> who showed rapid induction of nasal 197 cytokines which peaked within 24 hours after challenge but were undetectable by 48h (day 2) 198 indicating that protected older adults may show a slight delay in nasal cytokine responses to 199 200 pneumococcal challenge. Cytokine levels at baseline did not correlate with age in study participants 201 (Supplementary Fig. 3b).

202

## 203 Lack of monocyte recruitment in susceptible older adults after pneumococcal challenge

The nasal cell gene expression profiles suggested that older adults susceptible to pneumococcal colonization had higher levels of innate immune cell activation compared to protected older adults. Granulocytes are abundant in the nasal mucosa while monocytes are sparse with the later rapidly recruited after challenge in younger adults<sup>9,24</sup>.

We analysed the cellular composition of nasal cells by flow cytometry from nasal microbiopsies which were obtained in parallel to those used for transcriptome analysis. The overall number of leukocytes, granulocytes and monocytes as a ratio to epithelial cells<sup>9,25</sup> were comparable between younger and older adults before pneumococcal challenge (Fig. 4a). After challenge, there were no differences in

the proportion of leukocytes or granulocytes over the following 29 days between susceptible and protected study participants in either younger or older adults (Fig. 4b, c). In contrast to younger adults<sup>9</sup>, monocytes were not recruited into the nasal mucosa of susceptible older adults in response to pneumococcal challenge (Fig. 4d). These results are in line with the limited and variable induction

of CCL2 (MCP1) in susceptible older adults (Fig. 3a).

217 To gain a better understanding of granulocyte and monocyte subsets beyond the limited number of 218 surface markers used during flow cytometry, we applied deconvolution analysis of mixed cell 219 populations obtained in our bulk transcriptome data. Based on this analysis, mature neutrophils were 220 the most abundant granulocyte population in the nasal mucosa independent of carriage status and 221 timepoint (Fig. 4e, Supplementary Table S6). Myeloid cells were more heterogenous with CD141+ 222 cDC1 the most abundant population in both susceptible and protected study participants. 223 Intermediate monocytes appeared more abundant in susceptible participants at baseline. 224 Intermediate monocytes display an activated phenotype and are generally associated with more 225 inflammatory conditions. Notably, they were enriched in the nasal mucosa of older adults but not younger adults infected with Influenza A virus and correlated with age<sup>24</sup>. 226

227

## 228 Activation of neutrophils is associated with susceptibility to carriage in older adults

229 Since susceptible older adults showed enrichment of gene pathways associated with neutrophil 230 degranulation before challenge (Fig 1 and Fig. 2), we investigated the activation of granulocytes and 231 monocytes before (day -5) and after (days 2, 7, 9, 29) pneumococcal challenge. The expression level of CD16 - but not CD66b or HLA DR - was consistently lower on granulocytes of older adults susceptible 232 233 to pneumococcal colonization with significant lower levels observed at baseline and day 7 after challenge (Fig. 5a). Although FcyRIIIB can be stored in intracellular vesicle before rapid deployment 234 onto the cell membrane in response to activation<sup>26,27</sup>, higher expression of CD16 on granulocytes 235 positively correlated with gene expression levels for FCGR3B in protected but not susceptible older 236 237 adults at baseline (Fig. 5b). CD16 is rapidly cleaved from the surface following activation of 238 granulocytes indicating that these cells may have been already activated before challenge in older 239 adults susceptible to pneumococcal carriage.

Opsonisation, degranulation and radical oxygen species production are important defence mechanisms against colonization with pneumococcus<sup>28</sup>. To determine whether neutrophil degranulation increased after challenge with pneumococcus as we reported for younger adults<sup>9</sup>, we measured the concentration of myeloperoxidase (MPO), a soluble marker for degranulation of azurophil neutrophil granules, in nasal lining fluids. Before challenge, the concentration of MPO in the nasal lining fluid was 2-fold higher in older adults compared to younger adults (Fig. 5c). Unlike carriage-

positive younger adults, levels of MPO in the nasal lining fluid did not increase after challenge insusceptible older adults (Fig 5d).

248 Next, we asked whether expression levels of 66 genes associated with the neutrophil degranulation pathway within the M2 module correlated with the MPO concentration in nasal lining fluid (Fig. 5e). 249 250 MPO levels positively correlated with expression levels of neutrophil degranulation M2 module genes 251 in susceptible older adults before but not after challenge suggesting that granulocytes were refractory 252 to further activation. By contrast, in older adults protected from carriage, neutrophil degranulation 253 genes within the M2 module correlated with MPO levels after but not before challenge implying that 254 granulocytes became activated and contributed to clearance of pneumococci from the nose as we 255 reported previously<sup>8</sup>. Together these data indicate that neutrophils in susceptible older adults are in 256 a state of activation before challenge with limited responses to pneumococci after challenge.

257

## 258 Activation of monocytes is associated with susceptibility to carriage in older adults

Given the lack of monocyte recruitment, we analysed expression levels of CD14, CD16 and HLA-DR on monocytes. Expression levels of CD14 but not HLA-DR or CD16 were significantly lower on monocytes before challenge (day -5) in susceptible compared to protected study participants (Fig. 6) indicating a dominance of intermediate monocytes in the nasal mucosa of susceptible older adults in agreement with deconvolution analysis of nasal transcriptome data (Fig. 4e). In protected older adults, the expression levels of CD16 increased on Day2 after challenge (Fig. 6).

265

#### 266 Discussion

267 Exposure to respiratory pathogens occurs in the upper respiratory tract and immunological responses 268 here are critical for either the establishment or clearance of infection. Failure to clear infection 269 increases the risk of microaspiration of pathogens into the lung and development of pneumonia. Older 270 adults are at an increased risk of pneumococcal disease although rates, duration and densities of S. pneumoniae colonization in the upper respiratory tract are comparable or lower than those observed 271 272 in younger adults<sup>16,29</sup>. Age has been associated with cellular senescence which in turn drives 273 "inflammaging" akin to chronic inflammation with the release of proinflammatory cytokines and 274 increased vascular permeability<sup>14</sup>. Aging alters the innate immune response with changes in neutrophil recruitment into tissue, reduces phagocytosis and NETosis and reduced phagocytosis and 275 276 antigen presentation by macrophages and dendritic cells (reviewed in <sup>30</sup>). An alternative and not 277 necessarily contradictory view is that changes in cellular composition and response to recall antigens 278 during aging are appropriate adaption to life-long exposure to pathogens with "inflammaging" as an early sign of underlying disease independent of age <sup>31</sup>. Here we investigated the immune response in 279

All rights reserved. No reuse allowed without permission.

nasal tissue before and after pneumococcal controlled human infection in healthy older adults and
 compared results with existing data of younger adults<sup>9</sup>. Remarkably, we observed that older adults
 who became colonized presented with a susceptibility profile both at the transcriptional and cellular
 level before pneumococcal challenge.

Analysis of the nasal transcriptome revealed overexpression of genes associated with the reactome 284 285 pathway "neutrophil degranulation" in older susceptible adults compared to those protected from 286 pneumococcal colonization. Granulocytes, the majority of which are neutrophils, are abundant in the 287 nasal mucosa and the first line of defence against bacterial infection through mechanisms such as 288 antibody-mediated phagocytosis, production of radical oxygen species, degranulation and NETosis. 289 While the frequency of granulocytes remained unchanged before and after pneumococcal challenge 290 in older study participants, expression levels of genes associated with the reactome pathway 291 "neutrophil degranulation" positively corelated with MPO concentration in nasal lining fluid and negatively correlated with CD16 expression levels on granulocytes, both of which indicate higher 292 293 activation of neutrophils in the nasal mucosa of susceptible adults before pneumococcal challenge.

Although older adults had higher levels of MPO compared to younger adults before pneumococcal challenge, there were no differences between susceptible and protected older adults and were maintained at comparable level after challenge. It has been reported that with age, the microbiome of the nasal and oral cavity is no longer distinct<sup>32</sup> but whether this contributes to increases risk of disease is unknown. Although the exact driver of increased activation of neutrophils in susceptible older adults we report here require further investigation, it may result in local tissue damage which in turn may increase adhesion and micro-invasion of pneumococcus in the nasal mucosa<sup>33</sup>.

301 It is also noteworthy that the FCAR gene encoding the Fc $\alpha$ R was 3-fold overexpressed in susceptible adults before pneumococcal challenge. Although anti-pneumococcal secretory IgA is cleaved by the S. 302 303 pneumoniae IgA1 protease (ZmpA), it is an important opsonin for other viral and bacterial pathogens. 304 Gene expression levels of FCRG3A and FCGR3B, encoding FcyRIIIA expressed on NK cells and monocytes and FcyRIIIB expressed on neutrophils, increased two days after pneumococcal challenge 305 in susceptible study participants, although increased expression of CD16 (FcyRIII) was not evident at 306 the cellular level. It has been reported in other studies<sup>34,35</sup> that CD16 expression is reduced on 307 308 neutrophils from older adults and associated with reduced phagocytosis of pneumococcus. We observed that CD16 expression was generally lower in susceptible study participants only both before 309 310 and after pneumococcal challenge. CD16 is a GPI-anchored protein and rapidly shed from the surface 311 of granulocytes upon activation or apoptosis which may explain the discrepancy between 312 transcriptional and cellular data. CD16-mediated signalling upon crosslinking with immune complexes 313 depends on association of CD16 with CD32 (FcyRII). Shedding of CD16 may result in better accessibility

All rights reserved. No reuse allowed without permission.

of FcγRIIA (CD32) on the surface of neutrophils enhancing subsequent Fc-mediated phagocytosis or
 extracellular killing of bacteria<sup>36</sup>. Although the role of FcR-mediated phagocytosis by neutrophils in the
 nasal mucosa has to be confirmed at the functional level, we speculate that increased expression of
 Fc-receptors on nasal neutrophils of susceptible older adults after colonization onset may contribute
 to the clearance of pneumococci.

319 In our study, the concentration of both CXCL10 and the related cytokine CXCL9 were increased at the 320 protein level and transcriptional level in older susceptible adults compared to protected older adults 321 before pneumococcal challenge. CXCL10 and the closely related CXCL9 are largely induced by IFN<sub>Y</sub> and 322 chemoattractants for NK- and T cells, important for the clearance of viral infections. Increased 323 concentrations of CXCL10 have been reported in nasal lining fluid before challenge with RSV in those 324 who developed cold symptoms<sup>37</sup> and younger study participants receiving the nasal live attenuated influenza vaccine (LAIV) or with asymptomatic viral infection before pneumococcal challenge were 325 associated with increased pneumococcal load<sup>9</sup>. In a recent study evaluating the use of high levels of 326 327 CXCL10 in nasal lining fluids as a marker for undiagnosed viral infections, the authors detected a 328 distinct profile of high levels of CXCL10 together with neutrophilic inflammation in bacterial and viral 329 co-infections<sup>38</sup>. However, it is unlikely that the increased CXCL10 concentration in our study was due 330 to viral infection because individuals with an asymptomatic viral infection were excluded from our 331 analysis. The role of CXCL10 in bacterial infections is less clear. Increased CXCL10 concentrations were 332 also associated with pneumonia in animal models of pneumococcal disease and it is also a promising 333 marker which distinguished between CAP caused by Staphylococcus aureus or S. pneumoniae with higher levels detected in pneumococcal CAP<sup>39</sup>. Furthermore, CXCL10 can be produced by tissue-334 335 infiltrating neutrophils which express its receptor CXCR3 and acts on these neutrophils in an autocrine 336 fashion followed by degranulation, ROS production and chemotaxis thus contributing to airway 337 inflammation<sup>40</sup>.

High serum concentrations of CXCL9 are a strong predictor of cellular aging and cardio-vascular health even in healthy adults<sup>41</sup>. It is produced by endothelial cells, macrophages and neutrophils<sup>42</sup>. Whether CXCL9 is indicative of neutrophilic inflammation or produced by endothelial cells in the nasal mucosa in our study remains unclear but given its role in biological aging, its association with increased susceptibility to colonization with *S. pneumoniae* requires further investigation and if confirmed may offer an opportunity to identify older adults at greater risk of pneumococcal infection.

Another important observation was the lack of recruitment of monocytes into the nasal mucosa after pneumococcal challenge unlike younger adults<sup>9</sup>. It is not known whether CCL2 is not induced or expression of the CCL2 receptors CCR2 and CCR4 is impaired. However, both CCL2 and CCR2 expression on monocytes are crucial for additional recruitment of and clearance of pneumococcus by

monocytes<sup>43</sup>. A recent study in a mouse model pneumococcal pneumonia suggested that age is associated with higher expression of CCR2 on monocytes but reduced phagocytosis of *S. pneumoniae*<sup>44</sup>. Therefore, it will be important to analyse the phenotype and function of monocytes over the course of colonization in an experimental infection model in more detail, together with the frequency and function of dendritic cells, both in healthy younger and older adults since both populations play a role in the activation of adaptive immune responses both in the nasal mucosa and systemically.

Given that in our study population, older adults cleared pneumococcal infection from the nasal mucosa without showing higher bacterial densities or any discernible delay in colonization duration, the question arises how the above changes in the nasal mucosa at the cellular and transcriptional level reflect the increased risk of older adults to develop pneumococcal disease.

359 Although the upper and lower respiratory tract differ in composition in both type and frequency of 360 specialised epithelial cells and immune cells, there is sufficient overlap between compartments as assessed at the single cell level scRNAseq<sup>45-47</sup>. One possible explanation is that older adults have 361 physiological changes such as reduced mucocillary clearance and increased expression of host 362 receptors binding *S. pneumoniae* that leads to increased micro-aspiration into their lungs<sup>48–51</sup>. Micro-363 364 aspiration of pneumococcus into the lung may result in more pronounced inflammation with 365 increased tissue damage if neutrophils are recruited or activated in a similar manner to those observed in the nasopharynx. Neutrophils in the lung are found in increased frequency in the lung and 366 367 contribute to inflammation during bacterial and viral infections<sup>52-54</sup>. In addition, adults at risk of pneumonia have a delay in lung efferocytosis - the phagocytic clearance of apoptotic cells - following 368 community acquired pneumonia<sup>55</sup>. In a mouse model of pneumococcal and viral co-infection, older 369 370 mice showed rapid activation of neutrophils in the lung in the absence of increased bacterial burden 371 suggesting that dysregulation of immune responses are a major factor contributing to pneumonia<sup>56</sup>.

Understanding the role of individual pathogenic bacteria such as pneumococcus and its relationship with activation (or lack of) of immunological pathways that could result in increased susceptibility to pneumococcal disease are a prerequisite for future studies analysing in detail the interaction between bacterial and viral infection in clinically vulnerable populations, and thus improving diagnosis and treatment.

377

378 **Online Methods**:

#### 379 Study Design & Demographics

Healthy adults aged 50-84 were inoculated with an estimated 80,000 CFU per nostril of *Streptococcus pneumoniae* serotype 6B (strain BHN418 (29), GenBank accession number ASHP00000000.1) as

All rights reserved. No reuse allowed without permission.

previously described<sup>7,57</sup>. Key eligibility criteria included capacity to give informed consent, no immunocompromised state or contact with susceptible individuals or children, no pneumococcal or influenza vaccine or infection in the last 2 years and not having taken part in EHPC studies in the past 3 years. All volunteers gave written informed consent, and research was conducted in compliance with all relevant ethical regulations. Participants who carried non-experimental pneumococcal strains at baseline (day -5) or had a viral infection were excluded from all analyses. Ethical approval was provided by the East Liverpool National Health Service Research and Ethics

Committee (reference numbers 15/NW/0146 and 14/NW/1460) and Human Tissue Authority licensing
number 12548.

391 Detailed demographic data of older adults >50yrs can be found in Adler 2021<sup>16</sup>. For comparison, data 392 from younger adults who were part of a control group of an Influenza co-infection study were re-393 analysed<sup>9,18</sup>. Some data on baseline (day -5) nasal cell populations before inoculation with Spn6B were 394 presented in a pre-print<sup>58</sup> but the analysis of baseline nasal cell data presented here is sufficiently 395 different and substantially extends the data presented in the preprint.

396

#### 397 Determination of carriage

Nasal washes were performed at day -5 and on days 2, 7, 9, 14, 22 and 29 post-challenge and
 colonization determined by the presence of pneumococcus in nasal wash samples at any time point
 post-challenge up to and including day 29, detected using classical microbiology<sup>7,57</sup>.

401

#### 402 Nasal curettage

403 Nasal cells were collected on days -5, 2, 7, 9 and 29 by scraping the inferior turbinate from participants 404 consecutively using four curettes (Rhino-pro<sup>®</sup>, Arlington Scientific), as described previously<sup>25</sup>. Two 405 curette samples were collected into PBS + 5mM EDTA and 0.5% heat inactivated FBS for 406 immunophenotyping and an additional two curette samples were collected into RLT (Qiagen) and 407 stored at -80°C for transcriptome analysis.

408

# 409 Nasal Cell Immunophenotyping

410 Cells were dislodged from curettes and processed immediately. Briefly, the nasal cells were stained 411 for 15 minutes with LIVE/DEAD® Fixable Violet Dead Cell Stain (Thermofisher) before the addition of 412 a cocktail of monoclonal antibodies for 20 minutes at 4°C protected from light (Supplementary Table 413 S7) Following incubation, cells were washed (440g for 5 min) with 3mL PBS, filtered through a 70µm 414 mesh filter (ThermoFisher) and resuspended in 200µL Cell FIX<sup>™</sup> (BD Biosciences). Samples were 415 acquired on a LSR II cytometer (BD Biosciences) and analysed using Flowjo software version 10

All rights reserved. No reuse allowed without permission.

416 (Treestar). Compensation matrices were set using compensation beads (BD Biosciences and 417 Thermofisher). Samples with less than 500 CD45+ leukocytes or 250 EpCam+ epithelial cells were 418 excluded from analysis. To adjust for the variability of cells collected within and between study 419 participants, absolute cell counts of the target populations were normalized with the absolute number 420 of epithelial cells. The gating strategy is shown in Supplementary Fig. 5.

421

# 422 Anti-6B capsular polysaccharide IgG

423 Anti-6B CPS IgG titres were measured using a modification of the WHO enzyme-linked immunosorbent 424 assay (ELISA) protocol. Nasal wash (NW) samples and reference serum 89SF (US Food and Drug 425 Administration (FDA)) were depleted of cell wall polysaccharide (CWPS) antibodies by pre-absorption with 10µg/mL solution of CWPS (Statens Serum Institut, Copenhagen, Denmark) in phosphate-426 427 buffered saline (PBS) blocked with heat-inactivated foetal bovine serum (ThermoFisher, Basingstoke UK) for 30 minutes. 96-well plates (Maxisorp microtiter, Nunc, Roskilde, Denmark) were coated with 428 429 5µg/mL purified pneumococcal 6B capsular polysaccharide (Statens Serum Institut) overnight at 4°C, 430 washed and blocked with 1% BSA. Reference serum 89SF was serially diluted as a standard curve. 431 Samples and standards were transferred to plates and incubated for two hours at room temperature, 432 followed by three washes with PBS/0.05% Tween (PBS-T), before incubation with the secondary 433 antibody diluted 1:4000 (A9544; Sigma-Aldrich Corporation, Dorset, UK) for 90 minutes. Wells were 434 washed as before and developed by incubation with p-nitrophenylphosphate (Sigma-Aldrich 435 Corporation) for 15-20 minutes at room temperature. Optical densities were measured at 405nm using a FLUOstar Omega plate reader (BMG Labtech GmbH, Ortenberg, Germany). Samples were 436 437 analyzed in duplicate, and samples with a coefficient of variation (CV) of > 25% were excluded.

438

## 439 Nasal Fluid Multiplex Cytokine Measurement

Nasal lining fluid was collected using nasosorption filters (Nasosorption, Hunt Developments) and stored at -80°C. For detection of cytokines in the nasal lining fluid, nasosorption samples were eluted in 100µl assay buffer (Thermo Fisher Scientific) by centrifugation at 2800g for 10 minutes. The eluate was cleared by further centrifugation at 16,000g for 10 min. Samples were analysed on an LX200 using a 30-plex magnetic human Luminex cytokine kit (LHC6003M; Thermo Fisher Scientific) and analysed with xPonent3.1 software following the manufacturer's instructions. Samples were analysed in duplicate, and samples with a coefficient of variation (CV) of > 25% were excluded.

447

#### 448 Myeloperoxidase ELISA

All rights reserved. No reuse allowed without permission.

449 Levels of myeloperoxidase in the nasal wash were determined using the Human Myeloperoxidase 450 DuoSet ELISA Kit (R&D Systems, Abingdon, UK) following manufacturer's instructions. Briefly, 96-well 451 plates (Maxisorp microtiter, Nunc, Roskilde, Denmark) were coated with 4µg/mL capture antibody 452 overnight and blocked with 1% BSA in PBS for 1 hour at room temperature. Samples and standards 453 were incubated in assay plates for 2 hours at room temperature. Detection antibody (50ng/ml) was 454 added to the wells for 2 hours at room temperature, followed by 20 minutes incubation with 455 Streptavidin-HRP (1:200; Fisher Scientific) at room temperature. The plates were developed using 456 TMB-Turbo Substrate (Fisher Scientific) for 20 minutes and the reaction stopped by adding 2N H<sub>2</sub>SO4 457 in a 1:1 ratio. Optical density was measured at 450nm and corrected for optical imperfection (540nm). 458 All samples were run in duplicate with a CV <25%.

459

#### 460 Nasal Cell RNA Sequencing and Bioinformatic Analysis

RNA sequencing: Nasal cells were collected in RLT (QIAGEN) and stored at -80°C until extraction. RNA 461 462 extraction (RNeasy; QIAGEN), sample integrity assessment (Bioanalyzer; Agilent 2100), library 463 preparation and RNA sequencing (BGISEQ-500RS) were performed at the Beijing Genome Institute.

- 464 Quality control of raw sequencing data was done using FastQC tool. Mapping to a human reference 465 genome assembly (GRCh38) was done using STAR 2.5.0a<sup>59</sup>. Read counts from the resulting binary alignment map (BAM) files were obtained with featureCounts<sup>60</sup> using a general transfer format (GTF) 466 gene annotation from the Ensembl database<sup>61</sup>The R/Bioconductor package DESeq2 (version 1.34.0) 467 was used to identify differentially expressed genes among the samples after removing absent features 468 (zero counts in more than 75% of samples)<sup>62</sup>. Genes with a p-value of < 0.05 and an absolute fold-469 470 change of > 2.0 were identified as differentially expressed. The complete set of raw sequences were
- 471 deposited at the NCBI through BioProject (PRJNAXX).
- 472 Functional analysis: We performed two functional analysis approaches regarding the biological 473 pathways related to ageing or carriage status. Gene Set Variation Analysis (GSVA) was used to identify pathways independent of comparison between groups of samples using R package gsva (version 474 475 1.42.0) and log<sub>2</sub> count per million (CPM) matrix count, and the parameters kcdf="Gaussian", 476 min.sz=15, and max.sz=500. Gene Set Enrichment Analysis (GSEA) was used to identify which 477 pathways were represented in the ranked transcriptome (log<sub>2</sub> fold-change), independently of the DE cut-off<sup>63</sup> using R package fgsea (version 1.20.0). The criteria used for statistical enrichment for GSEA 478 479 were a p value < 0.05 and enrichment of at least five genes for each pathway. The database used for 480 functional analysis was Reactome, release 79 and Pathway Browser version 3.7<sup>50</sup>.
- 481 *Co-expression analysis*: For co-expression analysis, counts were normalized using log<sub>2</sub> counts per 482 million (CPM), and the log<sub>2</sub> fold-change was calculated for each time point in a subject-wise manner.

All rights reserved. No reuse allowed without permission.

The co-expression analysis was performed separately for each group (older and younger, using baseline, day 2, and day 9 after pneumococcal challenge and susceptible and protected samples) using the R /Bioconductor package CEMiTool (version 1.18.1)<sup>19</sup>. This package unifies the discovery and the analysis of co-expression gene modules, evaluating whether modules contain genes that are overrepresented by specific pathways or altered in a specific sample group. A p-value = 0.05 was applied for filtering genes with low expression levels.

- 489 *M2 CEMiTool module protein-protein interaction network*: To identify the relationship between genes 490 (protein-protein interaction) from M2 CEMiTool modules, we filtered which genes were differentially 491 expressed at least one comparison (susceptible vs protected at baseline, day 2 or day 9 after 492 challenge), and we used the networkanalyst.ca web-based tool (version 3.0). We used the "Gene List 493 Input" option, a list of M2 DE gene symbols and StringDB<sup>64</sup> to find the genes interaction evidence 494 under parameters, confidence score cutoff = 900, not required experimental evidence and zero-order 495 network to use just genes from the input list.
- 496 Deconvolution analysis: Cell type estimation was performed using the CIBERSORTx web-based tool<sup>65</sup>,
- 497 with log<sub>2</sub> count per million (CPM) gene expression and single-cell atlas data from sorted monocytes
- 498 cells<sup>66</sup> and bone marrow and mature neutrophils bulk sequencing<sup>67</sup> from healthy human donors. Both
   499 studies were used as a reference to predict cell type proportion.
- 500

#### 501 Statistical Analysis

To identify the correlation between a pair of features, we first imputed the missing data using the R
package missForest (version 1.5) and then calculated the Spearman rho coefficient and p values using
the R base function cor.test.

Two-tailed statistical tests were used throughout the study. For comparison between study groups, Mann Whitney test was used. For comparison of study participants within a group over time, Friedmann test with Dunn Hochberg correction was used. P values were considered significant at <0.05 unless stated otherwise. Data were analysed using GraphPad prism (version 9) or R studio (2021.09.2 Build 382) and R (version 4.1.2).

510

## 511 Acknowledgements

512 We thank all study participants for their contribution and generous donation of time and tissue 513 samples. We acknowledge the invaluable contribution of the clinical and laboratory team collecting 514 and processing samples. This study was funded by the Melinda Gates Foundation (grant OPP1117728); 515 the UK Medical Research Council (grant MR/M011569/1).

All rights reserved. No reuse allowed without permission.

# 517

# 518 **References**

519

520 1. Mitsi, E. *et al.* Nasal Pneumococcal Density Is Associated with Microaspiration and Heightened

- Human Alveolar Macrophage Responsiveness to Bacterial Pathogens. *Am J Respir Crit Care Med* 201,
   335–347 (2020).
- 523 2. Wall, E. C., Chan, J. M., Gil, E. & Heyderman, R. S. Acute bacterial meningitis. *Curr Opin Neurol* 34,
  524 386–395 (2021).
- 3. Welte, T., Torres, A. & Nathwani, D. Clinical and economic burden of community-acquired
  pneumonia among adults in Europe. *Thorax* 67, 71 (2012).
- 4. Jain, S. *et al.* Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *New Engl J Medicine* **373**, 415–427 (2015).
- 5. Bijlsma, M. W. *et al.* Community-acquired bacterial meningitis in adults in the Netherlands, 2006–
  14: a prospective cohort study. *Lancet Infect Dis* 16, 339–347 (2016).
- 531 6. Torres, A. *et al.* Burden of pneumococcal community-acquired pneumonia in adults across Europe:
  532 A literature review. *Resp Med* 137, 6–13 (2018).
- 7. Ferreira, D. M. *et al.* Controlled human infection and rechallenge with Streptococcus pneumoniae
  reveals the protective efficacy of carriage in healthy adults. *Am J Respir Crit Care Med* **187**, 855–864
  (2013).
- 8. Nikolaou, E. *et al.* Experimental Human Challenge Defines Distinct Pneumococcal Kinetic Profiles
  and Mucosal Responses between Colonized and Non-Colonized Adults. *mBio* 12, (2021).
- 538 9. Jochems, S. P. *et al.* Inflammation induced by influenza virus impairs human innate immune
  539 control of pneumococcus. *Nat Immunol* 388, 1–14 (2018).
- 540 10. Jochems, S. P. *et al.* Innate and adaptive nasal mucosal immune responses following 541 experimental human pneumococcal colonization. *J Clin Invest* **130**, 4523–4538 (2019).
- 542 11. Pennington, S. H. *et al.* Polysaccharide-Specific Memory B Cells Predict Protection against
  543 Experimental Human Pneumococcal Carriage. *Am J Respir Crit Care Med* **194**, 1523–1531 (2016).
- 544 12. Wunderink, R. G. & Waterer, G. Advances in the causes and management of community acquired
  545 pneumonia in adults. *BMJ* 358, j2471 (2017).
- 546 13. Franceschi, C. & Campisi, J. Chronic Inflammation (Inflammaging) and Its Potential Contribution
  547 to Age-Associated Diseases. *J. Gerontol.: Ser. A* 69, S4–S9 (2014).
- 548 14. Fulop, T. *et al.* Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or
  549 Foes? *Front. Immunol.* 8, 1960 (2018).
- 15. Brooks, L. R. K. & Mias, G. I. Streptococcus pneumoniae's Virulence and Host Immunity: Aging,
  Diagnostics, and Prevention. *Front Immunol* 9, 1366 (2018).

- 16. Adler, H. *et al.* Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic. *Am J Respir Crit Care Med* **203**, 604–613 (2021).
- 17. Smith, E. L. *et al.* Upper airways colonisation of Streptococcus pneumoniae in adults aged 60
- 555 years and older: A systematic review of prevalence and individual participant data meta-analysis of 556 risk factors. *J Infect* **81**, 540–548 (2020).
- 18. Carniel, B. F. *et al.* Pneumococcal colonization impairs mucosal immune responses to live
  attenuated influenza vaccine. *Jci Insight* 6, e141088 (2021).
- 19. Russo, P. S. T. *et al.* CEMiTool: a Bioconductor package for performing comprehensive modular
   co-expression analyses. *BMC Bioinformatics* 19, 56 (2018).
- 20. Rasmussen, L. J. H., Petersen, J. E. V. & Eugen-Olsen, J. Soluble Urokinase Plasminogen Activator
  Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. *Front. Immunol.* **12**, 780641
  (2021).
- 21. Angata, T. Lectin in Host Defense Against Microbial Infections. *Adv. Exp. Med. Biol.* 1204, 215–
  230 (2020).
- 566 22. Brckalo, T. *et al.* Functional analysis of the CD300e receptor in human monocytes and myeloid
  567 dendritic cells. *Eur. J. Immunol.* 40, 722–732 (2010).
- 568 23. Hommes, T. J. *et al.* Triggering receptor expressed on myeloid cells-1 (TREM-1) improves host
  569 defence in pneumococcal pneumonia. *J. Pathol.* 233, 357–367 (2014).
- 570 24. Vangeti, S. *et al.* Human influenza virus infection elicits distinct patterns of monocyte and
  571 dendritic cell mobilization in blood and the nasopharynx. *Elife* **12**, e77345 (2023).
- 572 25. Jochems, S. P. *et al.* Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates
- Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection Compared to
  Nasal Wash. *PLoS ONE* 12, e0169805 (2017).
- 575 26. Tosi, M. F. & Zakem, H. Surface expression of Fc gamma receptor III (CD16) on chemoattractant-576 stimulated neutrophils is determined by both surface shedding and translocation from intracellular 577 storage compartments. *J. Clin. Investiq.* **90**, 462–470 (1992).
- 578 27. Jost, C. *et al.* Intracellular localization and de novo synthesis of FcRIII in human neutrophil
  579 granulocytes. *Blood* **75**, 144–151 (1990).
- 28. Simmons, S. R., Bhalla, M., Herring, S. E., Tchalla, E. Y. I. & Ghanem, E. N. B. Older but Not Wiser:
  the Age-Driven Changes in Neutrophil Responses during Pulmonary Infections. *Infect. Immun.* 89,
  (2021).
- 29. Almeida, S. T. *et al.* Low Prevalence of Pneumococcal Carriage and High Serotype and Genotype
  Diversity among Adults over 60 Years of Age Living in Portugal. *PLoS ONE* 9, e90974 (2014).
- 585 30. Bleve, A. *et al.* Immunosenescence, Inflammaging, and Frailty: Role of Myeloid Cells in Age-586 Related Diseases. *Clin Rev Allerg Immu* **64**, 123–144 (2023).

- 587 31. Pawelec, G. *et al.* The conundrum of human immune system "senescence." *Mech Ageing Dev*588 **192**, 111357–111357 (2020).
- 589 32. Whelan, F. J. *et al.* The Loss of Topography in the Microbial Communities of the Upper 590 Respiratory Tract in the Elderly. *Ann. Am. Thorac. Soc.* **11**, 513–521 (2014).
- 591 33. Weight, C. M. *et al.* Microinvasion by Streptococcus pneumoniae induces epithelial innate 592 immunity during colonisation at the human mucosal surface. *Nat Comms* **10**, 3060 (2019).
- 593 34. Simell, B. *et al.* Aging reduces the functionality of anti-pneumococcal antibodies and the killing of 594 Streptococcus pneumoniae by neutrophil phagocytosis. *Vaccine* **29**, 1929–1934 (2011).
- 595 35. Butcher, S. *et al.* Senescence in innate immune responses: reduced neutrophil phagocytic 596 capacity and CD16 expression in elderly humans. *J Leukoc Biol* **6**, 881–886 (2001).
- 36. Wang, Y. & Jönsson, F. Expression, Role, and Regulation of Neutrophil Fcγ Receptors. *Front Immunol* **10**, 1958 (2019).
- 37. Habibi, M. S. *et al.* Neutrophilic inflammation in the respiratory mucosa predisposes to RSV
  infection. *Science* **370**, (2020).
- 38. Cheemarla, N. R. *et al.* Nasal host response-based screening for undiagnosed respiratory viruses:
  a pathogen surveillance and detection study. *Lancet Microbe* 4, e38–e46 (2023).
- 39. Strehlitz, A., Goldmann, O., Pils, M. C., Pessler, F. & Medina, E. An Interferon Signature
  Discriminates Pneumococcal From Staphylococcal Pneumonia. *Front. Immunol.* 9, 1424 (2018).
- 40. Ichikawa, A. *et al.* CXCL10-CXCR3 Enhances the Development of Neutrophil-mediated Fulminant
  Lung Injury of Viral and Nonviral Origin. *Am. J. Respir. Crit. Care Med.* **187**, 65–77 (2013).
- 41. Sayed, N. *et al.* An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity,
  immunosenescence, frailty and cardiovascular aging. *Nat Aging* 1, 598–615 (2021).
- 42. Tecchio, C. & Cassatella, M. A. Neutrophil-derived chemokines on the road to immunity. *Semin. Immunol.* 28, 119–128 (2016).
- 43. Davis, K. M., Nakamura, S. & Weiser, J. N. Nod2 sensing of lysozyme-digested peptidoglycan
- promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. *J. Clin. Investig.* **121**, 3666–3676 (2011).
- 614 44. Puchta, A. *et al.* TNF Drives Monocyte Dysfunction with Age and Results in Impaired Anti-615 pneumococcal Immunity. *Plos Pathog* **12**, e1005368 (2016).
- 45. Poole, A. *et al.* Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. *J Allergy Clin Immun* **133**, 670-678.e12 (2014).
- 46. Lopez-Guisa, J. M. *et al.* Airway epithelial cells from asthmatic children differentially express
  proremodeling factors. *J. Allergy Clin. Immunol.* **129**, 990-997.e6 (2012).
- 47. Mihaylova, V. T. *et al.* Regional Differences in Airway Epithelial Cells Reveal Tradeoff between
- 621 Defense against Oxidative Stress and Defense against Rhinovirus. *Cell Rep.* **24**, 3000-3007.e3 (2018).

- 48. Svartengren, M., Falk, R. & Philipson, K. Long-term clearance from small airways decreases with age. *Eur. Respir. J.* **26**, 609–615 (2005).
- 49. Oliveira-Maul, J. P. de *et al.* Aging, Diabetes, and Hypertension Are Associated With Decreased
  Nasal Mucociliary Clearance. *Chest* 143, 1091–1097 (2013).
- 50. Schneider, J. L. *et al.* The aging lung: Physiology, disease, and immunity. *Cell* **184**, 1990–2019
  (2021).
- 51. Shivshankar, P., Boyd, A. R., Saux, C. J. L., Yeh, I. & Orihuela, C. J. Cellular senescence increases
  expression of bacterial ligands in the lungs and is positively correlated with increased susceptibility
  to pneumococcal pneumonia. *Aging Cell* **10**, 798–806 (2011).
- 52. Meyer, K. C., Rosenthal, N. S., Soergel, P. & Peterson, K. Neutrophils and low-grade inflammation
  in the seemingly normal aging human lung. *Mech. Ageing Dev.* **104**, 169–181 (1998).
- 53. Kulkarni, U. *et al.* Excessive neutrophil levels in the lung underlie the age-associated increase in
  influenza mortality. *Mucosal Immunol.* 12, 545–554 (2019).
- 54. Ouwendijk, W. J. D. *et al.* Neutrophils set extracellular traps to injure lungs in COVID-19. *J. Infect. Dis.* 223, jiab050- (2021).
- 55. Zheng, D. J., Taka, M. A. & Heit, B. Role of Apoptotic Cell Clearance in Pneumonia and
  Inflammatory Lung Disease. *Pathogens* 10, 134 (2021).
- 56. Joma, B. H. *et al.* A Murine Model for Enhancement of Streptococcus pneumoniae Pathogenicity
  upon Viral Infection and Advanced Age. *Infect. Immun.* 89, e00471-20 (2021).
- 57. Gritzfeld, J. F. *et al.* Density and duration of experimental human pneumococcal carriage. *Clin. Microbiol. Infect.* 20, O1145-51 (2014).
- 58. Reine, J. *et al.* Dynamic changes in innate immune and T cell function and composition at the
  nasal mucosa across the human lifespan. 2, 141–29 (2019).
- 59. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 646 60. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning 647 sequence reads to genomic features. *Bioinformatics* **30**, 923–930 (2014).
- 648 61. Yates, A. *et al.* Ensembl 2016. *Nucleic Acids Res* 44, D710–D716 (2016).
- 649 62. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-650 seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 651 63. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for 652 interpreting genome-wide expression profiles. *Proc National Acad Sci* **102**, 15545–15550 (2005).
- 64. Szklarczyk, D. *et al.* The STRING database in 2023: protein–protein association networks and
  functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* 51, D638–
  D646 (2022).

- 656 65. Newman, A. M. *et al.* Determining cell type abundance and expression from bulk tissues with 657 digital cytometry. *Nat. Biotechnol.* **37**, 773–782 (2019).
- 658 66. Villani, A.-C. *et al.* Single-cell RNA-seq reveals new types of human blood dendritic cells, 659 monocytes, and progenitors. *Science* **356**, eaah4573 (2017).
- 660 67. Grassi, L. et al. Dynamics of Transcription Regulation in Human Bone Marrow Myeloid
- Differentiation to Mature Blood Neutrophils. *Cell Rep.* **24**, 2784–2794 (2018).

662

All rights reserved. No reuse allowed without permission.



665

Fig. 1. Gene expression analysis of nasal cells showed distinct patterns in older 666 adults susceptible to carriage before pneumococcal challenge. a, Gene set 667 variance analysis (GSVA) of immune response pathways of nasal cells collected 668 669 before (day -5) and after (day 2, day 9) pneumococcal challenge of older and b, younger study participants who were protected (carriage-negative) or susceptible 670 (carriage-positive). Based on Euclidean distance calculation, we identified three 671 groups: group I contains gene sets associated predominantly with innate immune 672 responses, group II and III are enriched for gene 673

674

All rights reserved. No reuse allowed without permission.



All rights reserved. No reuse allowed without permission.

677 Fig. 2. Co-expression analysis of nasal cell transcripts using protection-status and timepoints samples for study participants. a, Co-expressed genes were determined by 678 CEMiTool (Co-Expression Module identification Tool), assessing normalised gene expression 679 profile using samples of protection-status (susceptible and protected), and across the 680 timepoints (baseline (day -5), day 2, and day 9 post-challenge) and Over-Representation 681 682 Analysis (enrichr function from R package clusterProfiler) to determine the biological function of each module genes using Reactome database (level 3 gene sets). Gene Set Enrichment 683 Analysis (GSEA) tool and z-score values for each gene across all timepoints were used to 684 determine whether module genes were positively (positive NES values) or negatively 685 686 (negative NES values) enriched. b, Protein-protein interaction network using 216 M2 modules and differentially expressed genes (susceptible vs protected samples) at at least one 687 688 timepoint. Genes are colour coded by Reactome pathway and those which were overexpressed at baseline are indicated by a black border. StringDB was used to determine 689 690 protein-protein interactions using default parameters, a confidence score cut-off of 900 and 691 not required experimental evidence (NetworkAnalysit.ca webtool). c. Heatmap showing log2 fold-change of overexpressed genes within each pathway before and after pneumococcal 692 challenge (susceptible vs protected samples). Criteria of differentially expressed genes were 693 694 absolute log2 fold-change > 1 and non-adjusted p value < 0.05.



All rights reserved. No reuse allowed without permission.

698 Fig. 3. Changes in cytokine concentration in the nasal lining fluid of older adults experimentally challenged with S. pneumoniae 6B. a, Line graphs showing the median 699 and interguartile range of cytokine concentrations in the nasal lining fluid in older study 700 participants before (day -5) and after (day 2, day 7 and day 9) pneumococcal challenge in 701 702 susceptible (light blue line, n=22) and protected (dark blue line, n=35) study participants. In 703 protected study participants, the concentration of IL-15 was higher at day 9 (Mann-Whitney U test, \* p=0.0344), and in susceptible study participants concentration of CXCL10 (IP-10) was 704 higher at day -5 and day 2 (Mann-Whitney U test, \* p=0.00116, \*\* p=0.0044) and the 705 concentration of CXCL9 (MIG) was higher at day -5 (Mann-Whitney U test, \* p=0.0419). No 706 differences were observed for CCL2 (MCP-1). b, Line graphs showing the median and 707 interguartile range of cytokine normalised gene expression (CPM= counts per million) in older 708 709 study participants before (day -5) and after (day 2, and day 9) pneumococcal challenge in susceptible (light blue line, n=18) and protected (dark blue line, n=24) study participants. In 710 711 susceptible study participants normalised gene expression of CXCL10 (IP-10) and CXCL9 (MIG) was higher at day -5 (DESeq2 Wald test, \* p=0.00303, \* p=0.0210, respectively), and 712 CCL2 was higher at day 9 (DESeq2 Wald test, \*\*\* p=0.000218). No differences were observed 713 for IL-15. c, Bar graph showing the level of cytokines at baseline and heatmap depicting log2 714 715 fold-change at day 2, 7, and 9 relatives to baseline (day -5) samples. The cytokines were grouped based on activity, adaptive, anti-inflammatory, chemokines, growth factors, and pro-716 inflammatory responses. The statistical test performed was the non-parametric Wilcoxon test. 717 One asterisk (\*) indicates p-value < 0.05, and two asterisk (\*\*) for p-value < 0.01. 718



720

Fig. 4. Recruitment of monocytes into the nasal mucosa of susceptible older adults is 721 722 impaired. a, In nasal micro-biopsies, the number of leukocytes, granulocytes and monocytes 723 was comparable between younger (green, n=91) and older adults (blue, n=38) before pneumococcal challenge (day -5). Cell numbers of each leukocyte subset were normalised to 724 epithelial cells as a ratio to account for differences in the total number of cells obtained for 725 726 each biopsy. b-d, Line graphs showing median and interquartile range of leukocytes, (b), granulocytes (c), and monocytes (d) in younger and older study participants before (day -5) 727 728 and after (day 2, day 7, day 9 and day 29) pneumococcal challenge in susceptible (young: 729 light green n= 28; old: light blue line, n=22) and protected (young: dark green, n=39; old: dark blue line, n=35) study participants. The proportion of monocytes increased at day 9 after 730 731 challenge in susceptible compared to protected younger adults (Mann Whitney U test, \* p=0.0122). This recruitment of monocytes into the nasal mucosa was not observed in 732 susceptible older adults (n=15). e, Deconvolution analysis of granulocytes and myeloid cells 733 734 using CIBERSORTx. Using normalised gene expression (log2 CPM (Counts Per Million)) and granulocytes and monocytes databases to determine the estimated cell population proportion. 735 P/M (promyelocytes/myelocytes); MM (metamyelocytes); BN (band neutrophils); SN 736 (segmented neutrophils) and PMN (polymorphonuclear). CD141 (CD141+ dendritic cells), 737 pDC (plasmacytoid dendritic cells), double negative (CD1c-CD141- dendritic cells), CD1C 738 (CD1c+ dendritic cells), mono (monocytes). 739







Fig. 5. Granulocytes are activated in older adults susceptible to pneumococcal 743 colonisation a, Line graph (median and interguartile range) of expression levels of CD16, 744 CD66b and HLA-DR on granulocytes before (day -5) and after challenge (day 2, day 7, day 9 745 746 and day 29) in protected (dark blue, n=34) and susceptible (light blue, n=22) older adults. The expression level of CD16 was significantly lower on nasal granulocytes at baseline and day 7 747 (Mann Whitney U test, baseline: p=0.034, day 7: p=0.014). b, Correlation between expression 748 749 levels of FCGR3B gene and CD16 Granulocyte levels in nasal lining fluid at baseline (day -5), 750 day 2 and day 9 in protected and susceptible study participants. c, At baseline (day -5), the 751 concentration of MPO (Myeloperoxidase) in nasal lining fluid in older adults (n=54) was higher

752 than in younger adults (n=30). Shown are dot plots with median and interguartile range, Mann 753 Whitney U test \*\* p=0.0085. d, The concentration of MPO did not change before or after 754 pneumococcal challenge in older study participants who became susceptible (light blue, n=22) or remained protected (dark blue, n=33). Line graph showing median and interguartile range 755 of MPO concentration before and after inoculation with pneumococcus. e, Correlation between 756 757 expression levels of 66 M2 module genes associated with the Reactome pathway "neutrophil degranulation" and MPO concentration in nasal lining fluid at baseline (day -5), day 2 and day 758 759 9 in protected and susceptible study participants.



761

Fig. 6. Monocytes are not recruited into the nasal mucosa after pneumococcal 762 challenge. a, Line graph (median and interquartile range) of expression levels of CD14, CD16, 763 and HLA-DR on monocytes before (day -5) and after challenge (day 2, day 7, day 9 and day 764 29) in protected (dark blue, n=25) and susceptible (light blue, n=14) older adults. The 765 expression level of CD14 was significantly lower on nasal monocytes at baseline (Mann 766 Whitney U test, baseline: p=0.0019). 767



770

Fig. S1: Study design. Study design showing inoculation of study participants with 771 Spn6B at day 0 and sample collection before (day -5) and after inoculation with Spn6B 772 (day 2, day 7, day 9, and day 29). Samples collected were nasal lining fluid 773 (nasosorption samples) for determination of the nasal inflammatory milieu and nasal 774 cells (nasal curettage) for immune phenotyping and analysis of the nasal 775 transcriptome. Study participants who remained protected (n=35) are depicted in dark 776 777





Fig. S2. Modules of co-expressed gene sets functional analysis. Over-Representation
 Analysis (ORA) was used to determine biological pathways (using Reactome level 3 gene
 sets) of co-expressed genes across all modules identified by CEMiTool.



785 Fig. S3. Cytokine concentration in the nasal lining fluid of older adults experimentally challenged with S. pneumoniae 6B. a, Line graphs showing the median and interquartile 786 787 range of cytokine concentrations in the nasal lining fluid in older study participants before (day -5) and after (day 2, day 7 and day 9) pneumococcal challenge in susceptible (light blue line, 788 n=22) and protected (dark blue line, n=35) study participants. b, Correlation plot of association 789 790 between age of protected and susceptible study participants with cytokine concentration 791 before (day -5) and after (day2 and day9) pneumococcal challenge. Correlation was tested using Spearman rho with Benjamin Hochberg adjustment for multiple comparison. 792

medRxiv preprint doi: https://doi.org/10.1101/2023.11.16.23298619; this version posted November 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



795

796 Fig. S4. Monocytes are not correlated with CCL2 levels into the nasal mucosa before 797 and after pneumococcal challenge. Scatter plot of the CCL2 level (pg/ml) and monocyte: epithelial cells ratio before (day -5) and after challenge (day 2, day 7, and day 9), which 798 showed no correlation in susceptible (light blue dots) and protected (dark blue dots) study 799 800 participants.



Fig. S5. Gating strategy for nasal cells of one representative study participant. 









![](_page_40_Figure_0.jpeg)

Monocyte : Epithelial cells log<sub>10</sub> ratio (rank values

![](_page_41_Figure_0.jpeg)

CD16hi 

Comp.APC.A -- CD16

102

Comp-PerCP-Cv5-5-A :: CD14

Comp.APC.A .. CD16